Want to see RHHBY full AI Analyst Report?
RHHBY Stock Chart & Stats
$57.47
$0.29(0.53%)
At close: 4:00 PM EDT
$57.47
$0.29(0.53%)
Day’s Range― - ―
52-Week Range$39.50 - $60.85
Previous CloseN/A
Volume747.71K
Average Volume (3M)2.19M
Market Cap
$345.44B
Enterprise Value$363.86K
Total Cash (Recent Filing)$9.70B
Total Debt (Recent Filing)$31.69B
Price to Earnings (P/E)23.2
Beta0.38
Next Earnings
Feb 04, 2027EPS Estimate
1.49Next Dividend Ex-DateN/A
Dividend Yield2.81%
Share Statistics
EPS (TTM)1.94
Shares Outstanding5,620,501,500
10 Day Avg. Volume2,667,749
30 Day Avg. Volume2,190,001
Financial Highlights & Ratios
PEG Ratio0.36
Price to Book (P/B)7.76
Price to Sales (P/S)4.15
P/FCF Ratio19.53
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$63.00Price Target Upside9.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)3.11
Revenue Forecast (FY)$77.55B
Bulls Say, Bears Say
Bulls Say
Clinical Trial ResultsEarly trontinemab data shows competitive amyloid clearance and improved ARIA rate versus peers, but clinical outcomes will determine success.
Financial PerformanceRoche's model was updated and numbers raised post recent business trends, with sales and EPS growth estimates increased.
Product EfficacyGazyva showed potential best-in-class profile in lupus nephritis and is likely to be the starter therapy of choice versus GSK's Benlysta.
Bears Say
Clinical Trial SafetyThere was a case of fatal cerebral macrohemorrhage in Part 2, leading to updated trial criteria to exclude patients with superficial siderosis.
Placebo ResponseThe high placebo response rate in males was notable, where placebo achieved a 66.7% complete renal response compared to 42.9% for Gazyva.
Roche Holding News
RHHBY FAQ
What was Roche Holding’s price range in the past 12 months?
Roche Holding lowest stock price was $39.50 and its highest was $60.85 in the past 12 months.
What is Roche Holding’s market cap?
Roche Holding’s market cap is $345.44B.
When is Roche Holding’s upcoming earnings report date?
Roche Holding’s upcoming earnings report date is Feb 04, 2027 which is in 153 days.
How were Roche Holding’s earnings last quarter?
Roche Holding released its earnings results on Jul 23, 2026. The company reported $1.661 earnings per share for the quarter, beating the consensus estimate of $1.601 by $0.06.
Is Roche Holding overvalued?
According to Wall Street analysts Roche Holding’s price is currently Undervalued.
Does Roche Holding pay dividends?
Roche Holding pays a Annually dividend of $1.55 which represents an annual dividend yield of 2.81%. See more information on Roche Holding dividends here
What is Roche Holding’s EPS estimate?
Roche Holding’s EPS estimate is 1.49.
How many shares outstanding does Roche Holding have?
Roche Holding has 5,620,501,500 shares outstanding.
What happened to Roche Holding’s price movement after its last earnings report?
Roche Holding reported an EPS of $1.661 in its last earnings report, beating expectations of $1.601. Following the earnings report the stock price went up 4.294%.
Which hedge fund is a major shareholder of Roche Holding?
Currently, no hedge funds are holding shares in RHHBY
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Roche Holding Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$63.00 (9.62% Upside)
$63.00 (9.62% Upside)
Blogger Sentiment
Bullish
RHHBY Sentiment 64%
Sector Average 60%
Sector Average 60%
Hedge Fund Trend
Decreased
By 3.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.7%
Last 30 Days ▲ 3.6%
Last 30 Days ▲ 3.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.93%
12-Months-Change
Fundamentals
Return on Equity
2.81%
Trailing 12-Months
Asset Growth
2.26%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Roche Holding
Roche Holding AG functions as a major global healthcare enterprise, primarily concentrating its efforts within the pharmaceutical and diagnostic sectors. The company boasts an extensive international presence, with key operations located in countries such as Switzerland, Germany, the United States, Austria, the Netherlands, the United Kingdom, France, and Belgium. Its pharmaceutical division is dedicated to creating and supplying a diverse array of therapeutic remedies. These target a broad spectrum of medical fields, including oncology, neuroscience, immunology, cardiovascular and metabolic disorders, ophthalmology, and respiratory ailments. The comprehensive product line further extends to treatments for specific conditions like infectious diseases, anemia, various dermatological issues, hemophilia, inflammatory and autoimmune disorders, neurological conditions, and transplantation-related needs. Within its diagnostics segment, Roche develops and markets a wide variety of laboratory-based tests designed to identify and monitor numerous illnesses. These include, but are not limited to, cancer, diabetes, Covid-19, hepatitis, and human papillomavirus. Additionally, the company is a provider of essential diagnostic instruments and reagents. Established in 1896, Roche Holding AG maintains its corporate headquarters in Basel, Switzerland.
RHHBY Company Deck
RHHBY Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
Overall the call conveyed a positive operating and pipeline momentum despite identifiable headwinds. Roche reported strong profitability (core op profit +10%, margin expansion), solid organic growth in Pharma, multiple regulatory wins (5 priority reviews) and major diagnostics and R&D milestones (AXELIOS launch, CE marks, strategic M&A). Offsetting items include China pricing reform and a weak respiratory season hitting Diagnostics, currency translation pressures, a near‑term net debt increase (timing effects) and some competitive/biosimilar pressure in specific franchises. On balance, the operational and pipeline achievements materially outweigh the manageable challenges described.View all RHHBY earnings summariesRHHBY Stock 12 Month Forecast
Average Price Target
$63.00
▲(9.62% Upside)
Technical Analysis
Ownership Overview
―
Insiders
0.54% Mutual Funds
0.08% Other Institutional Investors
99.34% Public Companies and
Individual Investors